Equities

Inotiv Inc

Inotiv Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.72
  • Today's Change-0.015 / -0.87%
  • Shares traded61.92k
  • 1 Year change-43.79%
  • Beta3.3928
Data delayed at least 15 minutes, as of Sep 20 2024 19:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

  • Revenue in USD (TTM)501.06m
  • Net income in USD-99.22m
  • Incorporated1975
  • Employees1.96k
  • Location
    Inotiv Inc2701 Kent AveWEST LAFAYETTE 47906-1350United StatesUSA
  • Phone+1 (317) 463-4527
  • Fax+1 (765) 497-1102
  • Websitehttps://www.inotivco.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Carisma Therapeutics Inc20.71m-72.50m40.74m107.00--113.16--1.97-1.78-1.780.50750.00870.2153----193,551.40-75.38-30.87-91.33-34.47-----350.08-255.66----0.8322---62.70---336.93--255.27--
HST Global Inc0.00-123.45k41.56m1.00---------0.0209-0.02090.00-0.00040.00-------3,300.80-5,836.01---------------27.315.81-------0.7858------
FibroGen Inc173.82m-168.32m41.77m486.00------0.2403-1.71-1.711.76-2.310.43011.2244.10357,644.00-42.40-30.62-89.79-42.3176.6593.52-98.60-119.081.24-12.47----4.99-7.053.21---20.67--
Kezar Life Sciences Inc7.00m-98.57m42.51m58.00--0.2818--6.07-1.35-1.350.09622.070.0316----120,689.70-44.47-32.54-47.84-34.09-----1,408.11-4,308.11----0.0634-------49.28--10.08--
DURECT Corp8.41m-15.80m42.52m47.00--8.44--5.06-0.5283-0.52830.28420.16230.21430.6827.26145,017.20-40.25-37.34-208.53-53.4480.8091.83-187.84-139.110.797-38.830.7135---55.67-10.9621.82---10.98--
Passage Bio Inc0.00-76.57m43.24m58.00--0.4774-----1.36-1.360.001.470.00----0.00-47.99-48.56-53.39-52.09------------0.00------25.02---43.53--
Reviva Pharmaceuticals Holdings, Inc.0.00-35.51m43.35m15.00---------1.30-1.300.00-0.20260.00----0.00-356.97---------------------------38.92------
Lantern Pharma Inc0.00-17.75m43.81m21.00--1.42-----1.65-1.650.002.870.00----0.00-40.79-28.83-44.71-30.17------------0.00-------11.93------
LAVA Therapeutics NV7.40m-24.18m44.17m37.00--1.03--5.97-0.8976-0.89760.27411.630.0689--3.23199,946.00-22.51---27.11--97.78---326.89------0.1257---65.09---31.55------
Calcimedica Inc0.00-12.59m44.51m14.00--3.22-----1.88-1.880.001.290.00----0.00-60.97-63.99-75.48-72.71------------0.00------3.51---44.35--
Atara Biotherapeutics Inc62.39m-181.05m44.91m165.00------0.7198-39.90-39.9013.06-22.610.3430.93142.60277,275.60-99.55-70.20-256.98-86.9480.14---290.20-1,559.330.2945-250.76-----86.51---20.95---49.14--
vTv Therapeutics Inc1.00m-20.18m44.94m16.00--2.73--44.94-6.81-6.810.27015.470.029--6.5462,500.00-73.77-111.84-170.69-------2,540.90-680.94----0.00---100.00---5.67------
Inotiv Inc501.06m-99.22m45.12m1.96k--0.2478--0.09-3.84-3.8419.447.000.6158.126.83256,297.70-12.11-23.84-19.28-29.2624.9329.31-19.70-33.240.2279-0.62340.6774--4.5285.1068.80--83.64--
Rallybio Corp299.00k-73.88m45.64m43.00--0.5703--152.63-1.79-1.790.00721.930.0025----6,953.49-61.57---67.23-------24,709.37------0.00-------11.87------
Data as of Sep 20 2024. Currency figures normalised to Inotiv Inc's reporting currency: US Dollar USD

Institutional shareholders

11.35%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20241.05m4.02%
American Century Investment Management, Inc.as of 30 Jun 2024295.59k1.14%
Columbia Management Investment Advisers LLCas of 30 Jun 2024268.09k1.03%
Kentucky Planning Partners LLCas of 30 Jun 2024238.14k0.92%
Geode Capital Management LLCas of 30 Jun 2024232.86k0.90%
BlackRock Fund Advisorsas of 30 Jun 2024209.27k0.81%
Luther King Capital Management Corp.as of 30 Jun 2024198.60k0.76%
Renaissance Technologies LLCas of 30 Jun 2024164.16k0.63%
Two Sigma Investments LPas of 30 Jun 2024151.78k0.58%
D. E. Shaw & Co. LPas of 30 Jun 2024147.88k0.57%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.